Preclinical trials using HSP90 inhibitors in several cancer models have demonstrated their ability to simultaneously inhibit multiple oncogenic signaling pathways including those involved in the canonical hallmarks of cancer [6]. This evidence concerns the gene HSP90AA1 and cancer.